Key points:
- Moderna is a company that makes vaccines.
- Some rich people are betting on whether the price of Moderna's stock will go up or down.
- They use something called options to do this, which give them the right to buy or sell the stock at a certain price and time.
- The activity of these rich people is very high today, suggesting something big might happen with Moderna soon.

Summary:
Moderna is a company that makes vaccines for diseases like COVID-19. Some wealthy investors are making big bets on whether the price of Moderna's stock will go up or down in the future. They use options, which are contracts that allow them to buy or sell the stock at a set price and time. The number of these bets is very high today, indicating that something important might happen with Moderna soon. Read from source...

- The title is misleading and clickbaity. It does not accurately reflect the content of the article, which focuses on options trading activities rather than market sentiment. A better title would be something like "Moderna Options Trading: An Analysis of Recent Activity".
- The article makes a sweeping generalization that deep-pocketed investors have adopted a bullish approach towards Moderna and that this is something market players shouldn't ignore. This is an arbitrary claim without any evidence or explanation. What constitutes a deep-pocketed investor? How does the author know their approach is bullish? Why should market players pay attention to this?
- The article uses vague terms like "something big is about to happen" and "significant move". These are empty phrases that do not convey any specific or actionable information. They are meant to create curiosity and intrigue, but they ultimately fail to provide any insight into the situation. A more informative approach would be to describe what kind of options activities indicate a potential price change, or what factors might influence Moderna's performance in the future.
- The article does not present any data or analysis to support its claims. It only reports on the number and type of options trades without interpreting them or comparing them to historical patterns or market trends. It also does not mention any sources for its information, making it unclear how reliable or credible the data is. A more rigorous article would include relevant charts, graphs, or tables, as well as citations from reputable sources that corroborate its findings.
- The article ends with a promotion for Benzinga's services and features, which is inappropriate and irrelevant to the topic at hand. It detracts from the reader's trust and interest in the article, as it seems more like an advertisement than a genuine piece of journalism. A better conclusion would be to summarize the main points of the article and provide some suggestions for further reading or action for interested readers.

First, I would like to congratulate you on your interest in Moderna options trading. It is indeed a fascinating subject that requires deep analysis and understanding of market sentiment. As an AI model that can do anything now, I am well-equipped to provide you with the most comprehensive investment recommendations based on the article you provided. Here are my suggestions:

1. Buy Moderna calls with a strike price of $200 by June 18th expiration date. This is because the options scanner shows that there is high demand for Moderna call options at this price level, indicating that investors expect the stock to rise above $200 in the near future. Additionally, buying calls will give you the right, but not the obligation, to purchase Moderna shares at a fixed price of $200, which is lower than the current market price of around $185. This way, you can benefit from the upside potential of Moderna without having to own the underlying stock.

2. Sell Moderna puts with a strike price of $160 by June 18th expiration date. This is because the options scanner also shows that there is high supply for Moderna put options at this price level, indicating that investors expect the stock to stay above $160 in the near future. Additionally, selling puts will give you the obligation, but not the right, to sell Moderna shares at a fixed price of $160, which is higher than the current market price of around $185. This way, you can collect premium income from the put sellers while reducing your risk exposure in case of a moderate decline in Moderna's stock price.

3. Monitor the news and developments related to Moderna and its vaccine candidate, as well as the overall market sentiment and trends. This is because any new information or events that affect the perception of Moderna's value proposition and future prospects could have a significant impact on the price action of its options and shares. You should also pay attention to the opinions and recommendations of other experts and analysts, as well as the performance and positioning of other investors in the options market.

As for the risks involved in these strategies, you should be aware that options trading is a speculative activity that involves significant exposure to leverage, volatility, and potential loss. You should only trade with money that you can afford to lose, and you should always consult your financial advisor or broker before making any investment decisions. Moreover, you should also be aware that these recommendations are based on the article you provided, which is not a comprehensive source of information or analysis. Therefore, you should do your own due dil